Refractory cholinergic urticaria successfully treated with ketotifen

Steven P. McClean, Eduardo E. Arreaza, Michael A. Lett-Brown, J. Andrew Grant

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Four patients with cholinergic urticaria associated with additional cardiorespiratory manifestations are described. Two patients reported cold, in addition to heat and exercise, as a factor inducing symptoms. Prospective exercise challenge documented a rise in plasma histamine sixfold to 20-fold above baseline values that accompanied onset of symptoms. All four subjects had proved refractory to conventional antihistamine therapy. Institution of ketotifen at doses ranging from 3 to 8 mg per day resulted in symptomatic improvement, and in all four subjects a repeat exercise challenge confirmed clinical improvement. In three subjects exercise challenge with ketotifen demonstrated blockade of mast cell-mediator release. Plasma histamine levels remained at baseline. In the fourth patient, histamine rose to about half the peak observed before ketotifen therapy. These findings confirm the observation that ketotifen is both an H1 histamine-receptor antagonist as well as a stabilizer of mast cell-mediator release. We speculate that ketotifen may prove more effective than conventional antihistamines in the management of severe urticaria. (J ALLERGY CLIN IMMUNOL 1989;83;738-41.).

Original languageEnglish (US)
Pages (from-to)738-741
Number of pages4
JournalThe Journal of Allergy and Clinical Immunology
Volume83
Issue number4
DOIs
StatePublished - 1989

Fingerprint

Ketotifen
Urticaria
Cholinergic Agents
Exercise
Histamine
Histamine Antagonists
Mast Cells
Histamine H1 Antagonists
Hot Temperature
Therapeutics

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Refractory cholinergic urticaria successfully treated with ketotifen. / McClean, Steven P.; Arreaza, Eduardo E.; Lett-Brown, Michael A.; Grant, J. Andrew.

In: The Journal of Allergy and Clinical Immunology, Vol. 83, No. 4, 1989, p. 738-741.

Research output: Contribution to journalArticle

McClean, Steven P. ; Arreaza, Eduardo E. ; Lett-Brown, Michael A. ; Grant, J. Andrew. / Refractory cholinergic urticaria successfully treated with ketotifen. In: The Journal of Allergy and Clinical Immunology. 1989 ; Vol. 83, No. 4. pp. 738-741.
@article{8136edd5311b422782c13b12785feb4b,
title = "Refractory cholinergic urticaria successfully treated with ketotifen",
abstract = "Four patients with cholinergic urticaria associated with additional cardiorespiratory manifestations are described. Two patients reported cold, in addition to heat and exercise, as a factor inducing symptoms. Prospective exercise challenge documented a rise in plasma histamine sixfold to 20-fold above baseline values that accompanied onset of symptoms. All four subjects had proved refractory to conventional antihistamine therapy. Institution of ketotifen at doses ranging from 3 to 8 mg per day resulted in symptomatic improvement, and in all four subjects a repeat exercise challenge confirmed clinical improvement. In three subjects exercise challenge with ketotifen demonstrated blockade of mast cell-mediator release. Plasma histamine levels remained at baseline. In the fourth patient, histamine rose to about half the peak observed before ketotifen therapy. These findings confirm the observation that ketotifen is both an H1 histamine-receptor antagonist as well as a stabilizer of mast cell-mediator release. We speculate that ketotifen may prove more effective than conventional antihistamines in the management of severe urticaria. (J ALLERGY CLIN IMMUNOL 1989;83;738-41.).",
author = "McClean, {Steven P.} and Arreaza, {Eduardo E.} and Lett-Brown, {Michael A.} and Grant, {J. Andrew}",
year = "1989",
doi = "10.1016/0091-6749(89)90008-0",
language = "English (US)",
volume = "83",
pages = "738--741",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",
publisher = "Mosby Inc.",
number = "4",

}

TY - JOUR

T1 - Refractory cholinergic urticaria successfully treated with ketotifen

AU - McClean, Steven P.

AU - Arreaza, Eduardo E.

AU - Lett-Brown, Michael A.

AU - Grant, J. Andrew

PY - 1989

Y1 - 1989

N2 - Four patients with cholinergic urticaria associated with additional cardiorespiratory manifestations are described. Two patients reported cold, in addition to heat and exercise, as a factor inducing symptoms. Prospective exercise challenge documented a rise in plasma histamine sixfold to 20-fold above baseline values that accompanied onset of symptoms. All four subjects had proved refractory to conventional antihistamine therapy. Institution of ketotifen at doses ranging from 3 to 8 mg per day resulted in symptomatic improvement, and in all four subjects a repeat exercise challenge confirmed clinical improvement. In three subjects exercise challenge with ketotifen demonstrated blockade of mast cell-mediator release. Plasma histamine levels remained at baseline. In the fourth patient, histamine rose to about half the peak observed before ketotifen therapy. These findings confirm the observation that ketotifen is both an H1 histamine-receptor antagonist as well as a stabilizer of mast cell-mediator release. We speculate that ketotifen may prove more effective than conventional antihistamines in the management of severe urticaria. (J ALLERGY CLIN IMMUNOL 1989;83;738-41.).

AB - Four patients with cholinergic urticaria associated with additional cardiorespiratory manifestations are described. Two patients reported cold, in addition to heat and exercise, as a factor inducing symptoms. Prospective exercise challenge documented a rise in plasma histamine sixfold to 20-fold above baseline values that accompanied onset of symptoms. All four subjects had proved refractory to conventional antihistamine therapy. Institution of ketotifen at doses ranging from 3 to 8 mg per day resulted in symptomatic improvement, and in all four subjects a repeat exercise challenge confirmed clinical improvement. In three subjects exercise challenge with ketotifen demonstrated blockade of mast cell-mediator release. Plasma histamine levels remained at baseline. In the fourth patient, histamine rose to about half the peak observed before ketotifen therapy. These findings confirm the observation that ketotifen is both an H1 histamine-receptor antagonist as well as a stabilizer of mast cell-mediator release. We speculate that ketotifen may prove more effective than conventional antihistamines in the management of severe urticaria. (J ALLERGY CLIN IMMUNOL 1989;83;738-41.).

UR - http://www.scopus.com/inward/record.url?scp=0024553977&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024553977&partnerID=8YFLogxK

U2 - 10.1016/0091-6749(89)90008-0

DO - 10.1016/0091-6749(89)90008-0

M3 - Article

VL - 83

SP - 738

EP - 741

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

IS - 4

ER -